

CORRECTION

Open Access



Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

Linglong Yin^{1,2}, Youhong Liu^{1,2}, Yuchong Peng^{1,2}, Yongbo Peng³, Xiaohui Yu^{1,2}, Yingxue Gao^{1,2}, Bowen Yuan^{1,2}, Qianling Zhu^{1,2}, Tuoyu Cao^{1,2}, Leye He⁴, Zhicheng Gong⁵, Lunquan Sun^{1,2}, Xuegong Fan⁶ and Xiong Li^{1,2,4*}

Correction to: J Exp Clin Cancer Res 37, 153 (2018)
<https://doi.org/10.1186/s13046-018-0810-7>

Published online: 22 February 2022

Following publication of the original article [1], the authors identified a minor error in Fig. 4; specifically:

- Fig. 4 b: Incorrect flow cytometry graphs of VEL (20uM) and SA + VEL were used; the figure has been corrected to use the correct graphs

The corrected figure is given here. The correction does not have any effect on the final conclusions of the paper.

Reference

1. Yin L, Liu Y, Peng Y, et al. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. *J Exp Clin Cancer Res*. 2018;37:153. <https://doi.org/10.1186/s13046-018-0810-7>.

Author details

¹Center for Molecular Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan, China. ²Hunan Key Laboratory of Molecular Radiation Oncology, Xiangya Hospital, Central South University, Changsha, China. ³State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China. ⁴Research Institute for Prostate Disease, Central South University, Changsha, China. ⁵Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China. ⁶Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China.

The original article can be found online at <https://doi.org/10.1186/s13046-018-0810-7>.

*Correspondence: lixiongyang@csu.edu.cn

⁴ Research Institute for Prostate Disease, Central South University, Changsha, China

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 4 Co-administration of SAHA and veliparib enhanced PCA cell apoptosis. PCA cells LNCaP, C4–2 and PC-3 were treated with SAHA and veliparib alone or in combination at the indicated doses for 4 days (**a** LNCaP, **b** C4–2, **c** PC-3, **d** VCaP, CWR22Rv1, DU145). Cells were stained with FITC-Annexin V antibody and counterstained with PI. The apoptotic cells were analyzed by flow cytometry. Representative dot plots of FITC-Annexin V/PI staining are shown. Graph shows mean apoptotic cells (Annexin-V+/PI+) ± SD. Experiments were performed in triplicate. Cell apoptosis was validated by testing the protein levels of cleaved PARP by western blotting (**a-d**). **p* < 0.05; ***p* < 0.01 (SAHA or Veliparib alone vs. co-treatment)